

TRANSDERMAL DELIVERY OF CANNABINOIDS

ABSTRACT OF THE DISCLOSURE

Disclosed is a method for relieving symptoms
5 associated with illness or discomfort associated with the
treatment of illness in a subject. The method includes
providing a cannabinoid composition and delivering the
cannabinoid transdermally to the subject. The
cannabinoid composition used in this method includes at
10 least one cannabinoid selected from the group consisting
of Δ^9 -THC, cannabinal, cannabidiol, nabilone,
levonantradol, (-)-HU-210, (+)-HU-210, 11-hydroxy- Δ^9 -THC,
 Δ^8 -THC-11-oic acid, CP 55,940, and R(+)-WIN 55,212-2.
Also disclosed is an occlusive body which includes an
15 impermeable backing and a rate-controlling microporous
membrane which together define a cavity in which a
cannabinoid is disposed. Methods for increasing the
concentration of cannabinoids or cannabinoid metabolites
in a subject and for assessing the permeability of skin
20 to cannabinoids are also described.